Compare AstraZeneca plc (AZN) vs Microchip Technology Inc. (MCHP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Microchip Technology Inc. — how do they compare? AstraZeneca plc trades at $166.76 (market cap $253.13B), while Microchip Technology Inc. trades at $88.28 (market cap $47.30B). The key difference: AstraZeneca plc is far larger — about 5.4× Microchip Technology Inc.'s market cap, and Microchip Technology Inc. pays the higher dividend (2.09%). Which is the better fit depends on your goals.
| AZN | MCHP | |
|---|---|---|
Market Cap | $253.13B | $47.30B |
Sector | Health | Technology |
52-Week High | $209.48 | $102.97 |
52-Week Low | $137.44 | $49.02 |
Enterprise Value | $279.37B | $52.60B |
Dividend Yield | 1.92% | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
Microchip Technology (MCHP) trades at $84.23, down 4.92% in the last session, with a bearish technical signal and support near $81. The company reported a net loss of -$500K in 2025 despite beating EPS estimates in recent quarters, while revenue declined to $4.40B. Analyst consensus remains strongly bullish with a $113.33 price target, supported by positive news on AI and aerospace demand.
MCHP faces near-term pressure from weak profitability and high debt, but long-term growth is supported by AI, data center, and aerospace exposure. Risks include cyclical semiconductor demand and execution challenges, yet institutional sentiment and recent product launches suggest potential recovery if earnings improve.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Microchip Technology Inc.
Microchip became an independent company in 1989 when it was spun off from General Instrument. More than half of revenue comes from MCUs, which are used in a wide array of electronic devices from remote controls to garage door openers to power windows in autos. The company's strength lies in lower-end 8-bit MCUs that are suitable for a wider range of less technologically advanced devices, but the firm has expanded its presence in higher-end MCUs and analog chips as well.
Read more on MCHP →
